The Bookout Center will focus on enhancing the use of robotics and imaging in medicine. Photo via Houston Methodist

A groundbreaking new institution is coming to Houston Methodist.

The Bookout Center will build on the success of the Houston Methodist Institute for Technology, Innovation and Education (MITIE).

The new center will focus on enhancing the use of robotics and imaging in medicine. Virtual reality, robotics, AI, and other technologies will all play a part in the support that The Bookout Center will provide for health care professionals at all levels and specialties. High-resolution imaging and diagnostics will also be part of the forward-thinking research center.

The Bookout Center, which will be housed in the Houston Methodist Academic Institute, is the result of an undisclosed donation amount from Ann and John F. Bookout III. At the age of 100, John’s father, also named John Bookout, is an active Houston Methodist Board member and served as its chair from 1991 until 2007.

“We’re excited and humbled to have the support of the Bookout family,” Marc L. Boom, president and CEO of Houston Methodist, says in a press release. “The Bookouts believe in what our physicians, researchers and scientists do to bring life-changing treatments to our patients and community, and this gift will help us build on our legacy of leading medicine. We are so very grateful for this gift.”

A medical director for The Bookout Center has already been named. The role will be filled by Alan Lumsden, the Walter W. Fondren III Presidential Distinguished Chair in the Houston Methodist DeBakey Heart & Vascular Center and Chair of the Department of Cardiovascular Surgery. Dr. Lumsden will work alongside Dr. Stuart Corr, newly appointed director of Innovation Engineering for The Bookout Center, and associate professor of Bioengineering, to develop, implement, and lead the center’s activities.

"The Bookout Center will complement our existing programs with robust research, clinical trials and the expertise to develop further innovation in these fields,” Lumsden says. “We are grateful to the Bookouts for giving us the opportunity to lead the world in developing and refining these life-saving technologies, which will continue to improve outcomes and recovery times for patients.”

The new institute will be run by director Alan Lumsden, the Walter W. Fondren III Presidential Distinguished Chair in the Houston Methodist DeBakey Heart & Vascular Center and Chair of the Department of Cardiovascular Surgery. Photo via TMC.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.